Table 2 Characteristics and genetic variation(s) of both index cases and relatives with AIP mutations.

From: Aryl hydrocarbon receptor interacting protein and syndromic gene variants detected in Turkish isolated pituitary adenoma families by whole exome sequencing

FIPA type

( index number)

Homogeneous

(6)

 

Heterogeneous       (12)

 

Heterogeneous           (13)

 

Cases

Index

Relative (Brother)

Index

Relative (Daughter)

Index

Relative (Sister)

Sex (F/M) / Age at diagnosis (yrs)

F/43

M/35

M/37

F/29

M/27

F/21

Complaint(s)

Hand-foot enlargement

Hand-foot enlargement

Headache

Secondary amenorrhea, Galactorrhea

Hand-foot enlargement

Severe headache (apoplectic event)

Phenotype

Acral

Acral

Acral

Only the nose looks a little wide ***

Acral

No feature

GH (ng/ml)

IGF-1 (ng/ml, range)

PRL (ng/ml)

4.2

454 (93–345)

6.4

NA

6.4

800 (94–210)

21.7

7.2

374 (117–329)

162

3.6

997 (232–385)

1350

-

-

222*

Size of adenoma (milimeters)

Knops

14

Grade 3

NA

23

Grade 4

12

Grade 3

40

Grade 4

25 (hemorrhagic adenoma)

Grade 3

Diagnosis

Acromegaly

Acromegaly

Acromegaly

Prolactinoma, Clinically silent acromegaly

Acromegaly (mix adenoma)

Prolactinoma

Treatment modalities

Surgery

Medical (duration)

Refused

SRL + DA (continues)

NA

TCS

SRL (156 months)

Refused

DA (continues)

2TSS + TCS

SRL + DA (continues)

TSS (apoplexia)

DA (12 months)

Pathology

IHCS

-

NA

GH (+) PRL (-) TSH (-) FSH/LH : (-) ACTH (+)

 

GH 40% (+) PRL 75% (+) TSH (-) FSH/LH : (-) ACTH ( - )

IHCS could not be performed due to hemorrhagic necrotic elements

Follow-up period (months)

132

NA

216

23

98

192

Latest hormonal status

Controlled under medication (SRL + DA)

NA

In remission (since 60 months)

DA could not be discontinued due to symptomatic PRL elevation, but IGF1 returned to normal (307 ng/ml)

Controlled under medication (SRL + DA)

In remission (since 180 months)

Latest residue tissue size (milimeters)

7

NA

9

Size did not change

18

0

Genetic variant(s)

      

AIP

c.910 C > T p.(Arg304Ter)

c.910 C > T p.(Arg304Ter)

Splice acceptor site c.646-1G > C**

Splice acceptor site c.646-1G > C **

c.241 C > T p.(Arg81Ter)

c.241 C > T p.(Arg81Ter)

SQSTM1

c.1001_1003del p.(Gly334del)

c.1001_1003del p.(Gly334del)

-

-

-

-

LGALS3

-

-

c.719T > C p.(Ile240Thr)

c.719T > C p.(Ile240Thr)

-

-

SUFU

-

-

c. 842 C > T

p.(Pro281Leu)

c. 842 C > T

p.(Pro281Leu)

-

-

  1. (*) Post-apoplexy level; IHCS: Immunohistochemical staining, (**) Novel AIP variant; (***) She complained only of symptoms of hyperprolactinemia, but her father had acromegaly; TSS, Transsphenoidal surgery; TCS, Transcranial surgery; SRL, Somatostatin receptor ligand; DA, Dopamine agonist; PEG, Pegvisomant; RT, Radiotherapy; NA: Not available (only a blood sample was provided) .